Herlapsa (Lapatinib) Tablet

Description

Description

This page contains brief details about the drug lapatinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Lapatinib was approved for the first time on Mar 13, 2007, by the U.S. FDA in combination with Capecitabine for treating advanced or metastatic breast cancer in women.

Mechanism of Action of Lapatinib

Lapatinib acts against the enzyme called tyrosine kinase. It prevents the Human epidermal growth factor receptor protein (HER2) and Epidermal growth factor receptors (EGFRs) from signaling, which breast cancer cells produce. It kills cancer cells and slows down their growth.

Uses of Lapatinib

Lapatinib is used to treat advanced or HER2 Positive metastatic breast cancer.

Lapatinib Dosage available

Lapatinib is available as a tablet and used in combination with Capecitabine. The recommended dose is 1,250 mg (5 tablets of Lapatinib 250 mg) given orally once daily on days 1 to 21. It is advisable to take it before or after taking the food. Swallow the tablet and do not crush, open, or dissolve them. Your doctor may advise you to temporarily reduce your dose or discontinue your therapy.